Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 436.99 Billion KRW | -4.5% |
| 2022 | 457.58 Billion KRW | -16.56% |
| 2021 | 548.38 Billion KRW | 56.36% |
| 2020 | 350.72 Billion KRW | -2.53% |
| 2019 | 359.83 Billion KRW | 25.01% |
| 2018 | 287.84 Billion KRW | 2.97% |
| 2017 | 279.55 Billion KRW | -0.85% |
| 2016 | 281.94 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 428.71 Billion KRW | -1.89% |
| 2024 Q2 | 438.27 Billion KRW | 2.23% |
| 2023 Q4 | 436.99 Billion KRW | -2.06% |
| 2023 FY | 436.99 Billion KRW | -4.5% |
| 2023 Q2 | 481.72 Billion KRW | 4.97% |
| 2023 Q1 | 458.91 Billion KRW | 0.29% |
| 2023 Q3 | 446.17 Billion KRW | -7.38% |
| 2022 Q1 | 511.04 Billion KRW | -6.81% |
| 2022 Q4 | 457.58 Billion KRW | -3.82% |
| 2022 Q3 | 475.78 Billion KRW | -0.69% |
| 2022 Q2 | 479.1 Billion KRW | -6.25% |
| 2022 FY | 457.58 Billion KRW | -16.56% |
| 2021 Q2 | 440.83 Billion KRW | -1.92% |
| 2021 Q3 | 446.74 Billion KRW | 1.34% |
| 2021 Q4 | 548.38 Billion KRW | 22.75% |
| 2021 FY | 548.38 Billion KRW | 56.36% |
| 2021 Q1 | 449.48 Billion KRW | 28.16% |
| 2020 Q1 | 362.75 Billion KRW | 0.81% |
| 2020 Q2 | 363.54 Billion KRW | 0.22% |
| 2020 FY | 350.72 Billion KRW | -2.53% |
| 2020 Q4 | 350.72 Billion KRW | -3.4% |
| 2020 Q3 | 363.06 Billion KRW | -0.13% |
| 2019 Q4 | 359.83 Billion KRW | 2.09% |
| 2019 Q3 | 352.46 Billion KRW | -0.58% |
| 2019 Q2 | 354.5 Billion KRW | 0.78% |
| 2019 Q1 | 351.75 Billion KRW | 22.2% |
| 2019 FY | 359.83 Billion KRW | 25.01% |
| 2018 Q2 | 300.15 Billion KRW | -4.27% |
| 2018 Q4 | 287.84 Billion KRW | 0.6% |
| 2018 Q1 | 313.53 Billion KRW | 12.15% |
| 2018 Q3 | 286.11 Billion KRW | -4.68% |
| 2018 FY | 287.84 Billion KRW | 2.97% |
| 2017 Q3 | 281.93 Billion KRW | 1.24% |
| 2017 Q1 | 281.12 Billion KRW | -0.29% |
| 2017 FY | 279.55 Billion KRW | -0.85% |
| 2017 Q2 | 278.49 Billion KRW | -0.94% |
| 2017 Q4 | 279.55 Billion KRW | -0.84% |
| 2016 FY | 281.94 Billion KRW | 0.0% |
| 2016 Q4 | 281.94 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -461.273% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 53.001% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 38.199% |
| HANDOK Inc. | 449.7 Billion KRW | 2.827% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -410.089% |
| Yuhan Corporation | 712.33 Billion KRW | 38.653% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 30.846% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -2649.352% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 48.699% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -716.377% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -112.262% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -481.335% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -195.678% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -520.721% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -461.273% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1099.342% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -73.997% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -98.0% |
| JW Holdings Corporation | 827.51 Billion KRW | 47.192% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 25.528% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -15.12% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -451.056% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -524.568% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -79.943% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -32.305% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -461.273% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 10.821% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 49.07% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -15.12% |
| Yuhan Corporation | 712.33 Billion KRW | 38.653% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 8.542% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -219.048% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 15.421% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -15.12% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -182.779% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -385.737% |
| CKD Bio Corp. | 170.76 Billion KRW | -155.911% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -79.292% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -177.181% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -915.816% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -451.056% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 30.912% |
| Boryung Corporation | 373.1 Billion KRW | -17.123% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -109.895% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -112.262% |
| JW Lifescience Corporation | 96.44 Billion KRW | -353.111% |